DESPUES DE 18 AÑOS CON SOLO TOPOTECAN CON FULL APPROVAL EN EEUU COMO TREATMENT 2a LÍNE SCLC-ES ... LA USFDA ACABA DE APROBAR AL TARLATAMAB CON FULL APPROVAL ... POR LO QUE ES YA EL NEW TREATMENT STÁNDARD EN EEUU . TIENE APROBACIÓNES ACELERADAS EN CANADA , UK, COREA ... Y EN DÍAS PODRÍA ALCANZAR LA APROBACIÓN TAMBIÉN EN CHINA QUE EN JULIO 2025, LA NMPA ACEPTÓ LA SOLICITUD DE REGISTRO (NDA) PARA TARLA OTORGÁNDOLE ADEMAS LA REVISIÓN PRIORITARIA . LA EMA TAMBIÉN LO ESTÁ YA EVALUANDO .
01 julio 2025
¡¡¡ DE CAMINO Y CON BUENA NOTA ... ANLOTINIB ORAL ( CAPSULA CON UN VASO DE AGUA ) PARA EL TRATAMIENTO DE SEGUNDA LINEA SMALL CELL LUNG CANCER ... !!! .
Hawaii Lung 2025 // Corey Langer MD Discusses lMForte Trial And Role Of LURBINECTEDIN In Maintenance SMALL CELL LUNG CANCER , "" HOWEVER TOXICITY IS NOT TRIVIAL "" , Questioning This SOC , CONCERN FOR TOXICITY , Lack Of Crossover And How To Sequence TARLATAMAB .
AQUI EL CURRÍCULUM Y LA OPINIÓN DEL DOCTOR COREY LANGER ... SOBRE LOS RESULTADOS PRESENTADOS DEL IMFORTE EN EL CONGRESO SOBRE PULMÓN EN HAWAI .
Corey J. Langer is a Professor of Medicine at the University of Pennsylvania, Perelman School of Medicine, where he serves as Clinical Director of Thoracic Oncology in the Abramson Cancer Center .
Professor Langer received his medical degree from Boston University in 1981 and completed his residency in medicine at the Graduate Hospital, University of Pennsylvania, and his hematology/oncology fellowship at Presbyterian University of Pennsylvania and Fox Chase Cancer Center in 1987 .
Professor Langer served in the Oncology division of Fox Chase Cancer Center from 1986–2008, leading its Thoracic Oncology Program from 1994–2008 . He moved to the University of Pennsylvania in 2008, where he currently leads clinical research efforts in thoracic malignancy as part of the Interdisciplinary Thoracic Oncology Program (I-TOP) and conducts research studies focused on the role of targeted therapy and immunotherapy in NSCLC .
Professor Langer is Co-Chair of the Medical Oncology Committee for NRG Cooperative Oncology Group and serves on the core thoracic committees of both NRG and ECOG .
Professor Langer is a Fellow of the American College of Physicians and is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC) .
For the past 34 years, since completing his fellowship, Professor Langer has led or co-led over 140 clinical trials in both SMALL CELL LUNG CANCER ( SCLC ) and NON-SMALL CELL LUNG CANCER ( NSCLC), as well as MESOTHELIOMA and HEAD and NECK CÁNCER .
Professor Langer has contributed numerous articles and abstracts to the medical literature and is the author or co-author of over 270 peer-reviewed peer-revie papers .
IAG Y EL SECTOR AÉREO Y AUTOMOVILÍSTICO DE ENHORABUENA ... EL PETROLEO CAE EN EL PRIMER SEMESTRE UN 9% ... Y SIGUE CAYENDO . Y AHORA VIENE LO MEJOR === Bombazo Geológico : Hallan un Yacimiento del ‘ Petróleo del Futuro ’ Valorado en 100.000 MILLONES de € en Francia .
Se trata de una forma específica de hidrógeno que podría ofrecer ventajas tanto económicas como medioambientales .
Este tipo de recurso, radicado en algunas zonas del planeta, plantea la posibilidad de un cambio de paradigma energético .
Un reciente hallazgo en Europa central, muy cerca de España, ha vuelto a ponerlo en el foco de los análisis y proyecciones de futuro . ...


.jpg)











